Toward Translation of Nanotechnology Cancer Interventions (TTNCI) (R01 Clinical Trial Not Allowed)

Funding Agency:
National Institutes of Health

This Funding Opportunity Announcement (FOA), entitled "Toward Translation of Cancer Nanotechnology Interventions (TTNCI)" is to enable the translation of nanotechnology-based cancer interventions relying on next-generation nanoparticle formulations and/or nano-devices. The TTNCI initiative encourages applications for advanced pre-clinical research, supporting translation of nanotechnology-based cancer diagnostics and therapeutics. The "Toward Translation of Nanotechnology Cancer Interventions" (TTNCI) awards are designed to mature experimental nanomedicines relying on "next-generation" nanoparticles and nano-devices which demonstrate strong potential to improve treatment effectiveness and/or tackle cancers that currently have a very limited arsenal of approved therapies or diagnostic strategies. TTNCI awards are expected to enable further development of proposed nanotechnology-based interventions to the stage in which they could continue on a developmental path towards the NCI Experimental Therapeutics (NExT) and other NCI translational programs.

Application Due Date(s): May 21, 2020; November 19, 2020; May 20, 2021; November 18, 2021‚Äč

PAR-20-116 Expiration Date November 19, 2021

Agency Website



Amount Description

Application budgets are limited to $475,000 in direct costs per year and need to reflect the actual needs of the proposed project

The maximum project period is 4 years.

Funding Type





Engineering and Physical Sciences
Environmental & Life Sciences
Medical - Translational

External Deadline

May 21, 2021